TCRX: tscan.com Company Value to Net Income
TScan Therapeutics (TCRX) develops personalized cell therapies to combat skin and lung tumors using the TargetScan system. The price action of the securities reflects the -0.10 metric. Research is based in US laboratories, where methods for detecting hidden targets are being refined. However, a high burn rate and the probability of side effects during testing render the project's commercial success a long-term hypothesis.
%20P%2FE%20Multiple&width=1200&height=400&colorIndex=0&v=mwbxec28.yq-7cu2wow&start=20220704&end=20261111&filename=GURU_Markets_-_TCRX_-_TScan-Therapeutics_-_PE-Multiple "TCRX: TScan Therapeutics Price to Earnings Ratio 07/04/2022 - 11/11/2026 | 👁️GURU.Markets👁️")
Comprehensive metric breakdowns and analytics for TScan Therapeutics Inc (TCRX)
- share price and expert price forecast:
- market capitalization information:
- balance sheet net asset value indicators:
- debt and solvency information:
All Debt to Shareholders' Equity Ratio TScan Therapeutics|TCRX - Long-Term Debt to Capital|Current Liabilities to Capital TScan|TCRX - Company Total Debt|Debt to Book Capital TScan Therapeutics, Inc.|TCRX - Company Long-Term Debt|Short-Term Debt Volume TScan Therapeutics|Quick Liquidity Indicator tscan.com
- company profitability and valuation multiples indicators:
TCRX - Net Profit|Projected Future Earnings TScan Therapeutics|TCRX - Price to Earnings Ratio|Price to Future Earnings Ratio TScan|TCRX - Price/Earnings to Growth Multiple|Business Value to Operating Income Before Depreciation TScan Therapeutics, Inc.|TCRX - Operating profit before deduction of amortization|Earnings per share for the last four quarters TScan Therapeutics|TCRX - Net earnings per share (EPS TTM)|Year-over-year earnings per one share growth for the last 12 months tscan.com|TCRX - Earnings growth in current year|Expected net earnings per share growth next year TScan Therapeutics
General company analysis:tscan.com, TCRX
TScan Therapeutics (TCRX) is developing capital-intensive cell therapy technologies, leveraging its robust R&D potential and academic staff. The P/E ratio here measures the market value of each unit of profit, reflecting the extent of the premium paid for future success or the risk of liquidity shortages; therefore, the company's P/E history serves as an indicator of capitalization resilience to volatility, helping investors determine the fair value assessment of the assets.
Analysis of competing companies
ONC: Company Value to Net Income|Price to Earnings Ratio HALO (Halozyme)|RVMD (Revolution Medicines Inc) - Company Value to Net Income|P/E Multiple AAPG (Ascentage)|CGON - Price to Earnings Ratio|URGN: Price to Earnings Ratio|BCAX - P/E Multiple|Personalis (PSNL) - Price to Earnings Ratio|Erasca Inc - Company Value to Net Income|DCTH (Delcath) - P/E Multiple|Market Cap to Earnings Y-mAbs Corp YMAB|Price to Earnings Ratio AURA (Aura Biosciences, Inc.)|Market Price to Net Income Ratio CADL|Price to Earnings Ratio Accuray ARAY|Business Payback Period SELLAS Life Sciences Group, Inc. (SLS)|Actuate Therapeutics, Inc - P/E Multiple|Citius Oncology Inc (CTOR) - Price to Earnings Ratio|HURA: P/E Multiple|protaratx.com (TARA) - P/E Multiple|Price to Earnings Ratio Fate Therapeutics|Price to Earnings Multiple WHWK (Aadi Bio)|Price to Earnings Ratio CSBR (Champions Oncology)|XBIT (xbiotech.com) - Company Value to Net Income|CEL-SCI - Price to Earnings Ratio|Market Price to Net Income Ratio OSTX (ostherapies.com)|Radiopharm Theranostics - P/E Multiple|Company Value to Net Income ARTV (Artiva Biotherapeutics, Inc.)|ANL: P/E Multiple|Market Cap to Earnings Veru Corporation (VERU)|Price to Earnings Ratio Tempest Therapeutics|XLO: Company Value to Net Income|P/E Multiple RENB|P/E Multiple muraloncology.com (MURA)|Price to Earnings Ratio Kairos Pharma KAPA|OKUR (OnKure Therapeutics, Inc.) - Market Cap to Net Income|CytoMed - P/E Multiple|Market Cap to Earnings Curis, Inc.|APLM (apollomicsinc.com) - Price to Earnings Ratio|Tharimmune Inc (THAR) - P/E Multiple|Price to Earnings Ratio ADVB|GNPX (Genprex Inc) - Market Price to Net Income Ratio|P/E Multiple CLDI|Business Payback Period sunshinebiopharma.com|P/E Multiple XBIO (Xenetic Biosciences, Inc.)|SLRX - Price to Earnings Ratio|PPBT - Price to Earnings Ratio|Business Payback Period American Oncology Network AONC|BGNE (BeiGene, Ltd.) - Price to Earnings Ratio|CKPT: Market Price to Net Income Ratio|ELEV (Elevation Oncology) - P/E Multiple|Price to Earnings Ratio iCAD Corp (ICAD)|Price to Earnings Ratio Ikena Oncology, Inc. (IKNA)|NTBL (Notable Labs Corp) - Company Value to Net Income|Viracta Therapeutics, Inc. - Price to Earnings Ratio|MOR: Price to Earnings Multiple|NAYA Biosciences Inc. - P/E Multiple|Ascentage Pharma Group International (AAPGV) - Price to Earnings Ratio
